Free Trial
NASDAQ:AVTX

Avalo Therapeutics Q1 2024 Earnings Report

Avalo Therapeutics logo
$5.02 -0.02 (-0.40%)
Closing price 04:00 PM Eastern
Extended Trading
$5.01 -0.01 (-0.20%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avalo Therapeutics EPS Results

Actual EPS
-$5.98
Consensus EPS
-$1.18
Beat/Miss
Missed by -$4.80
One Year Ago EPS
N/A

Avalo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Avalo Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Sunday, May 12, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Avalo Therapeutics' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Sunday, May 11, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Avalo Therapeutics Earnings Headlines

Seven new option listings and one option delisting on April 16th
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Avalo Therapeutics initiated with a Buy at Jefferies
See More Avalo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avalo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalo Therapeutics and other key companies, straight to your email.

About Avalo Therapeutics

Avalo Therapeutics (NASDAQ:AVTX), a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

View Avalo Therapeutics Profile

More Earnings Resources from MarketBeat